<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2025//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_250101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">40958912</PMID><DateCompleted><Year>2025</Year><Month>09</Month><Day>17</Day></DateCompleted><DateRevised><Year>2025</Year><Month>09</Month><Day>19</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Print">1664-2392</ISSN><JournalIssue CitedMedium="Print"><Volume>16</Volume><PubDate><Year>2025</Year></PubDate></JournalIssue><Title>Frontiers in endocrinology</Title><ISOAbbreviation>Front Endocrinol (Lausanne)</ISOAbbreviation></Journal><ArticleTitle>IDeglira vs insulin degludec for type 2 diabetes: a systematic review and meta-analysis.</ArticleTitle><Pagination><StartPage>1643386</StartPage><MedlinePgn>1643386</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">1643386</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3389/fendo.2025.1643386</ELocationID><Abstract><AbstractText Label="OBJECTIVES" NlmCategory="UNASSIGNED">This systematic review and meta-analysis was to evaluate and compare the efficacy and safety profiles of IDegLira versus insulin degludec in the management of type 2 diabetes (T2D).</AbstractText><AbstractText Label="METHODS" NlmCategory="UNASSIGNED">A comprehensive search was systematically conducted across PubMed, Embase, the Cochrane Library, and ClinicalTrials.gov from their inception until March 11, 2025. The search focused on randomized controlled trials (RCTs) that compared IDegLira with insulin degludec in adult patients with T2D. The primary outcomes of interest included change in glycated hemoglobin (HbA1c) and body weight. Random-effects meta-analyses were performed using RevMan 5.4 and Stata 16.0 software.</AbstractText><AbstractText Label="RESULTS" NlmCategory="UNASSIGNED">A total of six eligible RCTs, encompassing 3,393 patients (2,075 receiving IDegLira and 1,318 receiving insulin degludec), were included in the analysis. Treatment with IDegLira resulted in significant reductions in HbA1c (MD -0.79%, 95%CI: -1.03% to -0.54%), body weight (MD -1.62 kg, 95% CI: -2.13 kg to -1.11 kg), fasting plasma glucose (MD -0.45 mmol/L, 95% CI: -0.77 mmol/L to -0.14 mmol/L), self-measured plasma glucose (MD -1.00 mmol/L, 95% CI: -1.42 mmol/L to -0.59 mmol/L), and systolic blood pressure (MD -2.23 mmHg, 95% CI: -3.63 mmHg to -0.82 mmHg). In comparison to insulin degludec, IDegLira demonstrated superior blood glucose control, as evidenced by a higher proportion of patients achieving HbA1c levels below 7.0% and 6.5%, as well as those achieving these targets without weight gain and severe or blood glucose-confirmed hypoglycemic episodes. Additionally, patients treated with IDegLira required significantly lower daily insulin doses. Notably, the risk of severe or blood glucose-confirmed symptomatic hypoglycemia, adverse events, and severe adverse events was comparable between IDegLira and insulin degludec.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="UNASSIGNED">This meta-analysis provides compelling evidence that IDegLira offers superior glycemic control and more favorable effects on body weight compared to insulin degludec, while maintaining a comparable safety profile.</AbstractText><CopyrightInformation>Copyright &#xa9; 2025 Liu, Li, Yang, Qie, Wang, Wang and Zheng.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Liu</LastName><ForeName>Yang</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Pharmacy, Hebei Medical University Third Hospital, Shijiazhuang,&#xa0;China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Xuejing</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Department of Pharmacy, Hebei Medical University Third Hospital, Shijiazhuang,&#xa0;China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yang</LastName><ForeName>Jie</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Pharmacy, Hebei Medical University Third Hospital, Shijiazhuang,&#xa0;China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Qie</LastName><ForeName>Suhui</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Pharmacy, Hebei Medical University Third Hospital, Shijiazhuang,&#xa0;China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Xiaoli</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Department of Pharmacy, Hebei Medical University Third Hospital, Shijiazhuang,&#xa0;China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Xianying</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Department of Pharmacy, Hebei Medical University Third Hospital, Shijiazhuang,&#xa0;China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zheng</LastName><ForeName>Yingying</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Pharmacy, Hebei Medical University Third Hospital, Shijiazhuang,&#xa0;China.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D000078182">Systematic Review</PublicationType><PublicationType UI="D017418">Meta-Analysis</PublicationType><PublicationType UI="D003160">Comparative Study</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>09</Month><Day>01</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Front Endocrinol (Lausanne)</MedlineTA><NlmUniqueID>101555782</NlmUniqueID><ISSNLinking>1664-2392</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>54Q18076QB</RegistryNumber><NameOfSubstance UI="C571886">insulin degludec</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D049528">Insulin, Long-Acting</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D007004">Hypoglycemic Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C000613158">IDegLira</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D006442">Glycated Hemoglobin</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D001786">Blood Glucose</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C517652">hemoglobin A1c protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>839I73S42A</RegistryNumber><NameOfSubstance UI="D000069450">Liraglutide</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D004338">Drug Combinations</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003924" MajorTopicYN="Y">Diabetes Mellitus, Type 2</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D049528" MajorTopicYN="Y">Insulin, Long-Acting</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007004" MajorTopicYN="Y">Hypoglycemic Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016032" MajorTopicYN="N">Randomized Controlled Trials as Topic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006442" MajorTopicYN="N">Glycated Hemoglobin</DescriptorName><QualifierName UI="Q000032" MajorTopicYN="N">analysis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001786" MajorTopicYN="N">Blood Glucose</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001835" MajorTopicYN="N">Body Weight</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000069450" MajorTopicYN="N" AutoHM="Y">Liraglutide</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004338" MajorTopicYN="N" AutoHM="Y">Drug Combinations</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">IDegLira</Keyword><Keyword MajorTopicYN="N">insulin degludec</Keyword><Keyword MajorTopicYN="N">meta-analysis</Keyword><Keyword MajorTopicYN="N">randomized controlled trials</Keyword><Keyword MajorTopicYN="N">type 2 diabetes</Keyword></KeywordList><CoiStatement>The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2025</Year><Month>6</Month><Day>8</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2025</Year><Month>8</Month><Day>15</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>9</Month><Day>17</Day><Hour>6</Hour><Minute>34</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>9</Month><Day>17</Day><Hour>6</Hour><Minute>33</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>9</Month><Day>17</Day><Hour>4</Hour><Minute>46</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2025</Year><Month>9</Month><Day>1</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">40958912</ArticleId><ArticleId IdType="pmc">PMC12434752</ArticleId><ArticleId IdType="doi">10.3389/fendo.2025.1643386</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Magliano DJ, Boyko EJ. IDF Diabetes Atlas 10th edition scientific committee. In: IDF DIABETES ATLAS, 10th ed. International Diabetes Federation, Brussels: (2021).</Citation></Reference><Reference><Citation>Nolan CJ, Prentki M. Insulin resistance and insulin hypersecretion in the metabolic syndrome and type 2 diabetes: Time for a conceptual framework shift. Diabetes Vasc Dis Res. (2019) 16:118&#x2013;27. doi:&#xa0; 10.1177/1479164119827611, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/1479164119827611</ArticleId><ArticleId IdType="pubmed">30770030</ArticleId></ArticleIdList></Reference><Reference><Citation>Jia W, Weng J, Zhu D, Ji L, Lu J, Zhou Z, et al. Standards of medical care for type 2 diabetes in China 2019. Diabetes Metab Res Rev. (2019) 35:e3158. doi:&#xa0; 10.1002/dmrr.3158, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/dmrr.3158</ArticleId><ArticleId IdType="pubmed">30908791</ArticleId></ArticleIdList></Reference><Reference><Citation>Kamrul-Hasan ABM, Borozan S, Fernandez CJ, Dutta D, Nagendra L, Pappachan JM. Thrice-weekly insulin degludec versus once-daily insulin glargine in insulin-na&#xef;ve patients with type 2 diabetes mellitus: A systematic review and meta-analysis. Br J Hosp Med (Lond). (2025) 86:1&#x2013;16. doi:&#xa0; 10.12968/hmed.2024.0716, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.12968/hmed.2024.0716</ArticleId><ArticleId IdType="pubmed">40705560</ArticleId></ArticleIdList></Reference><Reference><Citation>Russell-Jones D, Pouwer F, Khunti K. Identification of barriers to insulin therapy and approaches to overcoming them. Diabetes Obes Metab. (2018) 20:488&#x2013;96. doi:&#xa0; 10.1111/dom.13132, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/dom.13132</ArticleId><ArticleId IdType="pmc">PMC5836933</ArticleId><ArticleId IdType="pubmed">29053215</ArticleId></ArticleIdList></Reference><Reference><Citation>Watkins JD, Koumanov F, Gonzalez JT. Protein- and calcium-mediated GLP-1 secretion: A narrative review. Adv Nutr. (2021) 12:2540&#x2013;52. doi:&#xa0; 10.1093/advances/nmab078, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/advances/nmab078</ArticleId><ArticleId IdType="pmc">PMC8634310</ArticleId><ArticleId IdType="pubmed">34192748</ArticleId></ArticleIdList></Reference><Reference><Citation>Gough SC, Bode B, Woo V, Rodbard HW, Linjawi S, Poulsen P, et al. Efficacy and safety of a fixed-ratio combination of insulin degludec and liraglutide (IDegLira) compared with its components given alone: results of a phase 3, open-label, randomised, 26-week, treat-to-target trial in insulin-naive patients with type 2 diabetes. Lancet Diabetes Endocrinol. (2014) 2:885&#x2013;93. doi:&#xa0; 10.1016/S2213-8587(14)70174-3, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2213-8587(14)70174-3</ArticleId><ArticleId IdType="pubmed">25190523</ArticleId></ArticleIdList></Reference><Reference><Citation>Aso Y, Takada Y, Tomotsune K, Chiba Y, Matsumura M, Jojima T, et al. Comparison of insulin degludec (IDeg)/insulin Aspart (IAsp) co-formulation therapy twice-daily with free combination of GLP-1 receptor agonist liraglutide plus insulin degludec in Tochigi: IDEAL Trial. Int J Clin Pract. (2021) 75:e13734. doi:&#xa0; 10.1111/ijcp.13734, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/ijcp.13734</ArticleId><ArticleId IdType="pubmed">33099848</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang W, Agner BFR, Luo B, Liu L, Liu M, Peng Y, et al. DUAL I China: Improved glycemic control with IDegLira versus its individual components in a randomized trial with Chinese participants with type 2 diabetes uncontrolled on oral antidiabetic drugs. J Diabetes. (2022) 14:401&#x2013;13. doi:&#xa0; 10.1111/1753-0407.13286, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/1753-0407.13286</ArticleId><ArticleId IdType="pmc">PMC9366571</ArticleId><ArticleId IdType="pubmed">35762390</ArticleId></ArticleIdList></Reference><Reference><Citation>Pei Y, Agner BR, Luo B, Dong X, Li D, Liu J, et al. DUAL II China: Superior HbA1c reductions and weight loss with insulin degludec/liraglutide (IDegLira) versus insulin degludec in a randomized trial of Chinese people with type 2 diabetes inadequately controlled on basal insulin. Diabetes Obes Metab. (2021) 23:2687&#x2013;96. doi:&#xa0; 10.1111/dom.14522, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/dom.14522</ArticleId><ArticleId IdType="pmc">PMC9291809</ArticleId><ArticleId IdType="pubmed">34387411</ArticleId></ArticleIdList></Reference><Reference><Citation>Watada H, Kaneko S, Komatsu M, Agner BR, Nishida T, Ranthe M, et al. Superior HbA1c control with the fixed-ratio combination of insulin degludec and liraglutide (IDegLira) compared with a maximum dose of 50&#x2009;units of insulin degludec in Japanese individuals with type 2 diabetes in a phase 3, double-blind, randomized trial. Diabetes Obes Metab. (2019) 21:2694&#x2013;703. doi:&#xa0; 10.1111/dom.13859, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/dom.13859</ArticleId><ArticleId IdType="pmc">PMC6900157</ArticleId><ArticleId IdType="pubmed">31423685</ArticleId></ArticleIdList></Reference><Reference><Citation>Liakopoulou P, Liakos A, Vasilakou D, Athanasiadou E, Bekiari E, Kazakos K, et al. Fixed ratio combinations of glucagon like peptide 1 receptor agonists with basal insulin: a systematic review and meta-analysis. Endocrine. (2017) 56:485&#x2013;94. doi:&#xa0; 10.1007/s12020-017-1293-6, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12020-017-1293-6</ArticleId><ArticleId IdType="pubmed">28401444</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu Y, Li X, Zheng Y, Wang X, Wang X. IDegLira for type 2 diabetes: a systematic review and meta-analysis. Endocrine. (2024) 83:648&#x2013;58. doi:&#xa0; 10.1007/s12020-023-03543-z, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12020-023-03543-z</ArticleId><ArticleId IdType="pubmed">37768513</ArticleId></ArticleIdList></Reference><Reference><Citation>Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. BMJ. (2009) 339:b2535. doi:&#xa0; 10.1136/bmj.b2535, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj.b2535</ArticleId><ArticleId IdType="pmc">PMC2714657</ArticleId><ArticleId IdType="pubmed">19622551</ArticleId></ArticleIdList></Reference><Reference><Citation>Liberati A, Altman DG, Tetzlaff J, Mulrow C, G&#xf8;tzsche PC, Ioannidis JP, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration. BMJ. (2009) 339:b2700. doi:&#xa0; 10.1136/bmj.b2700, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj.b2700</ArticleId><ArticleId IdType="pmc">PMC2714672</ArticleId><ArticleId IdType="pubmed">19622552</ArticleId></ArticleIdList></Reference><Reference><Citation>Hozo SP, Djulbegovic B, Hozo I. Estimating the mean and variance from the median, range, and the size of a sample. BMC Med Res Methodol. (2005) 5:13. doi:&#xa0; 10.1186/1471-2288-5-13, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1471-2288-5-13</ArticleId><ArticleId IdType="pmc">PMC1097734</ArticleId><ArticleId IdType="pubmed">15840177</ArticleId></ArticleIdList></Reference><Reference><Citation>Wan X, Wang W, Liu J, Tong T. Estimating the sample mean and standard deviation from the sample size, median, range and/or interquartile range. BMC Med Res Methodol. (2014) 14:135. doi:&#xa0; 10.1186/1471-2288-14-135, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1471-2288-14-135</ArticleId><ArticleId IdType="pmc">PMC4383202</ArticleId><ArticleId IdType="pubmed">25524443</ArticleId></ArticleIdList></Reference><Reference><Citation>
Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, et al. Cochrane handbook for systematic reviews of interventions version 6.2 (updated February 2021). London, United Kingdom: Cochrane;  (2021). Available online at: www.training.cochrane.org/handbook (Accessed August 24, 2025).</Citation></Reference><Reference><Citation>Buse JB, Vilsb&#xf8;ll T, Thurman J, Blevins TC, Langbakke IH, B&#xf8;ttcher SG, et al. Contribution of liraglutide in the fixed-ratio combination of insulin degludec and liraglutide (IDegLira). Diabetes Care. (2014) 37:2926&#x2013;33. doi:&#xa0; 10.2337/dc14-0785, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.2337/dc14-0785</ArticleId><ArticleId IdType="pubmed">25114296</ArticleId></ArticleIdList></Reference><Reference><Citation>Kaku K, Araki E, Tanizawa Y, Agner BR, Nishida T, Ranthe M, et al. Superior efficacy with a fixed-ratio combination of insulin degludec and liraglutide (IDegLira) compared with insulin degludec and liraglutide in insulin-na&#xef;ve Japanese patients with type 2 diabetes in a phase 3, open-label, randomized trial. Diabetes Obes Metab. (2019) 21:2674&#x2013;83. doi:&#xa0; 10.1111/dom.13856, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/dom.13856</ArticleId><ArticleId IdType="pmc">PMC6899795</ArticleId><ArticleId IdType="pubmed">31407845</ArticleId></ArticleIdList></Reference><Reference><Citation>Davies MJ, Aroda VR, Collins BS, Gabbay RA, Green J, Maruthur NM, et al. Management of hyperglycemia in type 2 diabetes, 2022. A consensus report by the american diabetes association (ADA) and the european association for the study of diabetes (EASD). Diabetes Care. (2022) 45:2753&#x2013;86. doi:&#xa0; 10.2337/dci22-0034, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.2337/dci22-0034</ArticleId><ArticleId IdType="pmc">PMC10008140</ArticleId><ArticleId IdType="pubmed">36148880</ArticleId></ArticleIdList></Reference><Reference><Citation>Chinese Diabetes Society . Guideline for the prevention and treatment of type 2 diabetes mellitus in China (2020 edition). Chin J Diabetes Mellitus. (2020) 13:315&#x2013;409. doi:&#xa0; 10.3760/cma.j.cn115791-20210221-00095</Citation><ArticleIdList><ArticleId IdType="doi">10.3760/cma.j.cn115791-20210221-00095</ArticleId></ArticleIdList></Reference><Reference><Citation>Ross SA. Breaking down patient and physician barriers to optimize glycemic control in type 2 diabetes. Am J Med. (2013) 126:S38&#x2013;48. doi:&#xa0; 10.1016/j.amjmed.2013.06.012, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.amjmed.2013.06.012</ArticleId><ArticleId IdType="pubmed">23953078</ArticleId></ArticleIdList></Reference><Reference><Citation>Coleman CI, Limone B, Sobieraj DM, Lee S, Roberts MS, Kaur R, et al. Dosing frequency and medication adherence in chronic disease. J Manag Care Pharm. (2012) 18:527&#x2013;39. doi:&#xa0; 10.18553/jmcp.2012.18.7.527, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.18553/jmcp.2012.18.7.527</ArticleId><ArticleId IdType="pmc">PMC10438207</ArticleId><ArticleId IdType="pubmed">22971206</ArticleId></ArticleIdList></Reference><Reference><Citation>Drummond R, Baru A, Dutkiewicz M, Basse A, Tengmark BO. Physicians&#x2019; real-world experience with IDegLira: results of a European survey. BMJ Open Diabetes Res Care. (2018) 6:e000531. doi:&#xa0; 10.1136/bmjdrc-2018-000531, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmjdrc-2018-000531</ArticleId><ArticleId IdType="pmc">PMC6014227</ArticleId><ArticleId IdType="pubmed">29942526</ArticleId></ArticleIdList></Reference><Reference><Citation>Weng J, Xiao D, Chen Y. Cost-utility of IDegLira versus alternative basal insulin intensification therapies in patients with type 2 diabetes mellitus uncontrolled on basal insulin in a Chinese setting. Diabetol Metab Syndr. (2025) 17:156. doi:&#xa0; 10.1186/s13098-025-01722-8, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13098-025-01722-8</ArticleId><ArticleId IdType="pmc">PMC12083176</ArticleId><ArticleId IdType="pubmed">40380308</ArticleId></ArticleIdList></Reference><Reference><Citation>Billings LK, Doshi A, Gouet D, Oviedo A, Rodbard HW, Tentolouris N, et al. Efficacy and safety of IDegLira versus basal-bolus insulin therapy in patients with type 2 diabetes uncontrolled on metformin and basal insulin: the DUAL VII randomized clinical trial. Diabetes Care. (2018) 41:1009&#x2013;16. doi:&#xa0; 10.2337/dc17-1114, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.2337/dc17-1114</ArticleId><ArticleId IdType="pubmed">29483185</ArticleId></ArticleIdList></Reference><Reference><Citation>Philis-Tsimikas A, Billings LK, Busch R, Portillo CM, Sahay R, Halladin N, et al. Superior efficacy of insulin degludec/liraglutide versus insulin glargine U100 as add-on to sodium-glucose co-transporter-2 inhibitor therapy: A randomized clinical trial in people with uncontrolled type 2 diabetes. Diabetes Obes Metab. (2019) 21:1399&#x2013;408. doi:&#xa0; 10.1111/dom.13666, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/dom.13666</ArticleId><ArticleId IdType="pmc">PMC6593861</ArticleId><ArticleId IdType="pubmed">30761720</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>